HF10 Treatment of Chronic Knee Pain

Chronic Pain Post-Procedural Clinical Trial

— CPSP-3  

Official title:

HF10 Therapy for the Treatment of Chronic, Focal, Neuropathic Pain Following Orthopedic Surgical Intervention of the Knee(s) - A Multicenter, Prospective Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04020211
• Other study ID #: CA2018-5 US CPSP-3
• Status: Terminated
• Start date: March 14, 2019
• Est. completion date: December 12, 2019

Study information

• Verified date: November 2020
• Source: Nevro Corp
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a multi-center study where patients who meet the eligibility criteria will be treated with HF10 therapy for their chronic knee pain post-orthopedic surgery. The primary endpoint will be assessed at 3 months, but observational assessments will continue until study completion at 12 months following implant.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: December 12, 2019
• Est. primary completion date: December 12, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

1. Have been diagnosed with chronic, focal, neuropathic pain following orthopedic surgery(ies) of the knee(s).

2. Average pain intensity (over a period of 7 days) of =5 out 10 cm on the Visual Analog Scale (VAS) in the primary area of pain at enrollment.

3. Have a score of at least 4 out of 10 in Douleur Neuropathique 4 (DN4) questionnaire at the time of enrollment or eligibility verification.

4. Deemed not to have surgical loosening or other complications from the surgery that affect the stability of the knee.

5. Have stable neurological status measured by motor, sensory and reflex function as determined by the investigator.

6. Be on stable pain medications, as determined by the Investigator, for at least 28 days prior to assessing pain intensity as described in inclusion criterion #2, and be willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device.

Key Exclusion Criteria:

1. Have radiculopathy or radicular leg pain resulting from failed back surgery.

2. Have a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator (such as primary headache diagnosis or fibromyalgia).

3. Have a current diagnosis of a progressive neurological disease such as multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, acute herniating disc, severe spinal stenosis and brachial plexus avulsion as determined by the Investigator.

4. Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure as determined clinically by the Investigator.

5. Have any prior experience with SCS.

6. Have objective evidence of epidural scarring and/or any signs or symptoms of myelopathy as determined by the investigator.

7. Be benefitting from an interventional procedure to treat their trunk or limb pain (Subjects should be enrolled at least 30 days from last benefit).

8. Have an existing drug pump and/or another active implantable device such as a pacemaker.

9. Be involved in an injury claim under current litigation.

10. Have an active or unsettled worker's compensation claim.

Related Conditions & MeSH terms

• Chronic Pain
• Chronic Pain Post-Procedural

Intervention

Device:
• Senza HF10 Therapy
Senza 10kHz Spinal Cord Stimulation

Locations

Country	Name	City	State
United States	Pain Management	Greenfield	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
Nevro Corp

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Responders and Improvement in Oxford Knee Score (OKS)	The OKS is a patient self-completion patient reported outcome containing 12 questions on activities of daily living with a recall period of 4 weeks. The OKS has been developed and validated specifically to assess function and pain after total knee replacement. The higher the score indicates improvement. The proportion of implanted subjects who are responders (achieved = 50% pain relief) to HF10 therapy for treatment of their chronic, post-surgical knee pain or reporting at least a 4-point improvement in their Oxford Knee Score (OKS).	3 months
Secondary	Change in Disability and Functioning	Percentage and average change from Baseline in Oxford Knee Score	3, 6, and 12 months
Secondary	Change in Functioning	Average change in walking distance assessed by 6-minute Walk Test	3 and 12 months
Secondary	Change in Functioning	Change in Global Assessment of Functioning	3 and 12 months
Secondary	Change in pain relief as measured by the Visual Analog Scale (VAS)	Percentage and average change from Baseline in knee pain intensity	3 and 12 months
Secondary	Change from baseline in pain experience: Short-Form McGill Pain Questionnaire (SF-MPQ-2) scores	The Short Form McGill Pain Questionnaire version 2 (SF-MPQ-2, hereafter referred to as MPQ) is a well validated and widely used questionnaire used to measure the major symptoms of pain. Subjects will be asked to rate the intensity of each of 22 pain descriptors from 0 (do not experience, or none) to 10 (worst possible) at follow-up visits outlined in the schedule of events.; Four subscale scores (continuous pain, intermittent pain, predominantly neuropathic pain, and affective descriptors) and a total score will be calculated. The lower the score indicates improvement (less interference from pain). Each subject's baseline scores will be compared to the scores at study visits. Mean change from baseline will be calculated for the entire cohort.; Percentage and average change from Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ-2) scores	3 and 12 months
Secondary	Global Impression of Change	Subject's impression of change in overall health condition as measured by the Patient and Clinician Global Impression of Change	3 and 12 months
Secondary	Change in Quality of Life as measured by the EuroQol five-dimensional questionnaire (EQ-5D-5L)	The 5-level EQ-5D version (EQ-5D-5L) uses a 2-part assessment: a descriptive one and a visual analog scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The higher the score indicates an improved in quality of life. Change from Baseline in health-related quality of life evaluation	3 and 12 months
Secondary	Change in Sleep as measured by the Pain and sleep Questionnaire (PSQ)	PSQ is an eight-item questionnaire developed to assess the impact of pain on sleep. PSQ-3 is a subset of PSQ, consisting of questions 1, 4 and 5 and has been validated to assess impact of chronic pain on sleep. The lower the score indicates improvement by less interference of sleep from pain. Change from baseline in 3-item pain and sleep questionnaire	3 and 12 months
Secondary	Medication	Change from baseline in opioid equivalent medication usage	3 and 12 months
Secondary	Safety profile: Incidence of AEs over time	Incidence of AEs over time	3, 6 and 12 months
Secondary	Safety profile: Neurological assessment over time by a physician and exam	Neurologic status includes testing for gross motor, sensory and appropriate reflex functions, which will be characterized as improved, maintained, or a deficit as compared with baseline status as follows: A clinically meaningful neurological improvement is defined as a significant persistent improvement in neurological function that impacts subject's well-being is attributable to a neurological finding; and is new or improved as compared with the baseline assessment. A clinically meaningful neurological deficit is defined as a stimulation-related significant persistent abnormality in neurological function that impacts subject's well-being is attributable to a neurological finding; and is new or worsened as compared with the baseline assessment. If neither a clinically meaningful neurological improvement nor a clinically meaningful neurological deficit is observed, then neurologic status is maintained.	3, 6 and 12 months